ArticleAnnals of medicine2025

24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China.

Jiantao Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.